AusperBio Announces Major Progress in AHB-137 Clinical Development
AHB-137, empowered by AusperBio’s proprietary Med-OligoTM ASO technology platform, holds the potential as a backbone in the quest for a functional cure for CHB. This novel dual-mechanism ASO has been evaluated in two Phase 1a/1b clinical trials in parallel, one in China and another outside China. To date, 122 participants, including 30 CHB patients, have…